Safety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation Triall. (2026). Sriwijaya Journal of Ophthalmology, 8(2), 478-485. https://doi.org/10.37275/sjo.v8i2.137